EUVIMEDEUVIMED entdecken
Crossref

Digital Transformation Disclosure, Product Innovation, and Market Performance: Financial Evidence from Indonesian State-Owned Pharmaceutical Cases

Muhammad Iqbal Ismail, Denies Susanto, Indar Riyanto

Greenation Computer and Information Review · 05.09.2026 · 2 (2) · 90-100

DOI: 10.38035/gcir.v2i2.861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Greenation Computer and Information Review, online erschienen am 05.09.2026. Verfasst von Muhammad Iqbal Ismail und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Digital transformation and product innovation may support pharmaceutical market performance, but research expenditure, product activity and realised sales are different measures. This study examines their reporting relationship in Kimia Farma and Phapros through a longitudinal documentary comparison of public reports covering 2021–2025. The detailed comparison uses 2024–2025 expense and sales information. Kimia Farma’s observed research expense increases from 45.52 to 47.34 billion rupiah after combining separately reported manufacturing and administrative lines, while revenue declines by 7.20 percent. Phapros’ manufacturing research expense decreases from 49.17 to 26.55 billion, while revenue rises by 26.34 percent. In Phapros, ethical and over the counter products account for the largest absolute sales increases, but the report does not isolate revenue generated by newly launched products. Digital narratives describe enabling infrastructure and customer channels rather than measured innovation returns. The contribution is a stage specific measurement framework that separates digital enablement, research input, product launch and commercial conversion. The findings do not identify a causal innovation effect or equate lower research expenditure with lower innovation capability.

Zitieren

APA

Ismail, M. I., Susanto, D., & Riyanto, I. (2026). Digital Transformation Disclosure, Product Innovation, and Market Performance: Financial Evidence from Indonesian State-Owned Pharmaceutical Cases. Greenation Computer and Information Review, 2(2), 90-100. https://doi.org/10.38035/gcir.v2i2.861

Vancouver

Ismail MI, Susanto D, Riyanto I. Digital Transformation Disclosure, Product Innovation, and Market Performance: Financial Evidence from Indonesian State-Owned Pharmaceutical Cases. Greenation Computer and Information Review. 2026;2(2):90-100. doi:10.38035/gcir.v2i2.861

BibTeX
@article{Ismail2026,
  author = {Ismail, Muhammad Iqbal and Susanto, Denies and Riyanto, Indar},
  title = {Digital Transformation Disclosure, Product Innovation, and Market Performance: Financial Evidence from Indonesian State-Owned Pharmaceutical Cases},
  journal = {Greenation Computer and Information Review},
  year = {2026},
  volume = {2},
  number = {2},
  pages = {90--100},
  doi = {10.38035/gcir.v2i2.861}
}
Kostenlos starten →